BBS-Bioactive Bone Substitutes Oyj (BONEH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BBS-Bioactive Bone Substitutes Oyj (BONEH) has a cash flow conversion efficiency ratio of -0.416x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.58 Million ≈ $-1.84 Million USD) by net assets (€3.79 Million ≈ $4.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View BONEH stock price and chart for real-time trading data and today's change.
BBS-Bioactive Bone Substitutes Oyj - Cash Flow Conversion Efficiency Trend (2015–2023)
This chart illustrates how BBS-Bioactive Bone Substitutes Oyj's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see BONEH market cap overview for the company's overall valuation and market capitalisation.
BBS-Bioactive Bone Substitutes Oyj Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BBS-Bioactive Bone Substitutes Oyj ranked by their cash flow conversion efficiency. Also see BONEH asset base for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fram Skandinavien AB Series B
ST:FRAM-B
|
-2.899x |
|
Rainy Mountain Royalty Corp
V:RMO
|
-0.024x |
|
Pharos Energy plc
LSE:PHAR
|
0.058x |
|
INCUVO S.A. ZY -50
F:68X
|
0.135x |
|
WILDCAT PRETR.LS -000028
F:8Y6
|
N/A |
|
Jiuzi Holdings Inc
NASDAQ:JZXN
|
-0.105x |
|
Heritage Distilling Holding Company, Inc.
NASDAQ:IPST
|
-0.076x |
|
Fjordland Exploration Inc
V:FEX
|
2.832x |
Annual Cash Flow Conversion Efficiency for BBS-Bioactive Bone Substitutes Oyj (2015–2023)
The table below shows the annual cash flow conversion efficiency of BBS-Bioactive Bone Substitutes Oyj from 2015 to 2023. Review BONEH financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €5.11 Million ≈ $5.97 Million |
€-2.92 Million ≈ $-3.42 Million |
-0.572x | +13.21% |
| 2022-12-31 | €4.27 Million ≈ $4.99 Million |
€-2.82 Million ≈ $-3.29 Million |
-0.659x | +4.93% |
| 2021-12-31 | €3.63 Million ≈ $4.25 Million |
€-2.52 Million ≈ $-2.95 Million |
-0.693x | -74.58% |
| 2020-12-31 | €6.09 Million ≈ $7.12 Million |
€-2.42 Million ≈ $-2.83 Million |
-0.397x | +15.30% |
| 2019-12-31 | €3.08 Million ≈ $3.60 Million |
€-1.44 Million ≈ $-1.69 Million |
-0.469x | -21.77% |
| 2018-12-31 | €4.42 Million ≈ $5.16 Million |
€-1.70 Million ≈ $-1.99 Million |
-0.385x | +61.34% |
| 2017-12-31 | €1.08 Million ≈ $1.26 Million |
€-1.08 Million ≈ $-1.26 Million |
-0.996x | -738.64% |
| 2016-12-31 | €4.60 Million ≈ $5.37 Million |
€-546.00K ≈ $-638.33K |
-0.119x | -23.33% |
| 2015-12-31 | €4.46 Million ≈ $5.22 Million |
€-430.00K ≈ $-502.72K |
-0.096x | -- |
About BBS-Bioactive Bone Substitutes Oyj
BBS-Bioactive Bone Substitutes Oyj, a biomedical technology company, develops, manufactures, and commercializes bioactive medical devices and implants for orthopedic surgery in Finland. It offers ARTEBONE, an orthobiological product based on tricalcium phosphate and natural spectrum of bone proteins used primarily for the treatment of bone defects and healing problems in extremities, such as foot… Read more